Patents by Inventor Sergey Y. Tetin

Sergey Y. Tetin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200209250
    Abstract: The disclosure provides methods of analyzing an analyte of interest in a biological sample using fluorescent agents and macroconjugates which comprise a core containing a cross-linked polymer or protein, tags, specific binding members or fragments thereof, and optionally carrier proteins. Also provided are methods of analyzing two or more analytes of interest in a biological sample in a single assay using microparticles and detection conjugates comprising different fluorophore labels, acquiring transmitted light and fluorescent images of the microparticles, and using a customized image analysis process to analyze the acquired images.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 2, 2020
    Inventors: Qiaoqiao Ruan, Patrick J. Macdonald, Kerry M. Swift, Sergey Y. Tetin, Brenda Calfin, Zhen Lin, Richard Haack, Mark R. Pope, John Prostko, Xiaoxing Qiu, Felicia Bogdan
  • Publication number: 20190195798
    Abstract: A method for analyzing the results of a ligand-receptor binding assay comprising the steps of: (a) providing the results of a ligand-receptor binding assay; and (b) qualifying the results of a ligand-receptor binding assay. More particularly, the ligand-receptor binding assay involves the steps of combining appropriate reagents in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is directly proportional to the amount of ligand present in the sample. Alternatively, the ligand-receptor binding assay involves the steps of combining appropriate reagents to perform a ligand-receptor binding assay in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is inversely proportional to the amount of analyte present in the sample.
    Type: Application
    Filed: December 31, 2018
    Publication date: June 27, 2019
    Inventors: Qiaoqiao Ruan, Sylvia C. Saldana, Joseph P. Skinner, Sergey Y. Tetin
  • Patent number: 10190986
    Abstract: A method for analyzing the results of a ligand-receptor binding assay comprising the steps of: (a) providing the results of a ligand-receptor binding assay; and (b) qualifying the results of a ligand-receptor binding assay. More particularly, the ligand-receptor binding assay involves the steps of combining appropriate reagents in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is directly proportional to the amount of ligand present in the sample. Alternatively, the ligand-receptor binding assay involves the steps of combining appropriate reagents to perform a ligand-receptor binding assay in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is inversely proportional to the amount of analyte present in the sample.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: January 29, 2019
    Assignee: Abbott Laboratories
    Inventors: Qiaoqiao Ruan, Sylvia C. Saldana, Joseph P. Skinner, Sergey Y. Tetin
  • Publication number: 20190004041
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 3, 2019
    Applicant: ABBOTT LABORATORIES
    Inventors: Barry L. DOWELL, Susan GAYDA, Qiaoqiao RUAN, Joseph P. SKINNER, Sergey Y. TETIN
  • Patent number: 10073090
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: September 11, 2018
    Assignee: ABBOTT LABORATORIES
    Inventors: Barry L. Dowell, Susan Gayda, Qiaoqiao Ruan, Joseph P. Skinner, Sergey Y. Tetin
  • Patent number: 9575077
    Abstract: The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: February 21, 2017
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Patent number: 9575076
    Abstract: The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: February 21, 2017
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Publication number: 20160109466
    Abstract: The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Application
    Filed: October 30, 2015
    Publication date: April 21, 2016
    Applicant: Abbott Point of Care Inc.
    Inventors: Dan WANG, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Publication number: 20160109465
    Abstract: The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Application
    Filed: October 29, 2015
    Publication date: April 21, 2016
    Applicant: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Publication number: 20160054317
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Application
    Filed: September 2, 2015
    Publication date: February 25, 2016
    Applicant: ABBOTT LABORATORIES
    Inventors: Barry L. DOWELL, Susan GAYDA, Qiaoqiao RUAN, Joseph P. SKINNER, Sergey Y. TETIN
  • Patent number: 9201078
    Abstract: The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: December 1, 2015
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Patent number: 9199234
    Abstract: The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: December 1, 2015
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Patent number: 9157910
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 13, 2015
    Assignee: Abbott Laboratories
    Inventors: Barry L. Dowell, Susan Gayda, Qiaoqiao Ruan, Joseph P. Skinner, Sergey Y. Tetin
  • Patent number: 9005901
    Abstract: Provided herein are kits and methods for assays with internal calibration.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 14, 2015
    Assignee: Abbott Laboratories
    Inventors: Susan Gayda, Qiaoqiao Ruan, Joseph P. Skinner, Sergey Y. Tetin
  • Patent number: 8846036
    Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: September 30, 2014
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Robert N. Ziemann, Frank C. Grenier, Ryan F. Workman, Lowell Tyner
  • Publication number: 20140273035
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventors: Barry L. DOWELL, Susan GAYDA, Qiaoqiao RUAN, Joseph P. SKINNER, Sergey Y. TETIN
  • Publication number: 20140273272
    Abstract: Provided herein are kits and methods for assays with internal calibration.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: ABBOTT LABORATORIES
    Inventors: Susan GAYDA, Qiaoqiao RUAN, Joseph P. SKINNER, Sergey Y. TETIN
  • Publication number: 20120308997
    Abstract: A method for analyzing the results of a ligand-receptor binding assay comprising the steps of: (a) providing the results of a ligand-receptor binding assay; and (b) qualifying the results of a ligand-receptor binding assay. More particularly, the ligand-receptor binding assay involves the steps of combining appropriate reagents in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is directly proportional to the amount of ligand present in the sample. Alternatively, the ligand-receptor binding assay involves the steps of combining appropriate reagents to perform a ligand-receptor binding assay in which receptors attached to a solid support, a sample suspected of containing a ligand, and a conjugate comprising a label form a complex in which the label is present at a concentration that is inversely proportional to the amount of analyte present in the sample.
    Type: Application
    Filed: June 6, 2011
    Publication date: December 6, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Qiaoqiao Ruan, Sylvia C. Saldana, Joseph P. Skinner, Sergey Y. Tetin
  • Publication number: 20120301896
    Abstract: The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Application
    Filed: November 29, 2011
    Publication date: November 29, 2012
    Applicant: ABBOTT POINT OF CARE INC.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Publication number: 20120301905
    Abstract: The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Application
    Filed: November 29, 2011
    Publication date: November 29, 2012
    Applicant: ABBOTT POINT OF CARE INC.
    Inventors: Dan Wang, Gordan Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin